CA2887928A1 - Compound comprising a mao targeting/seeker moiety for treating human gliomas - Google Patents
Compound comprising a mao targeting/seeker moiety for treating human gliomas Download PDFInfo
- Publication number
- CA2887928A1 CA2887928A1 CA2887928A CA2887928A CA2887928A1 CA 2887928 A1 CA2887928 A1 CA 2887928A1 CA 2887928 A CA2887928 A CA 2887928A CA 2887928 A CA2887928 A CA 2887928A CA 2887928 A1 CA2887928 A1 CA 2887928A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- mao
- chemotherapeutic
- cells
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VUTMVGCVSCMCMQ-QUBRTAAFSA-N CCC(C1C2)c3cc(O)ccc3NC1C(CC(C1COC3=O)[C@]3(CC)O)N2C1=O Chemical compound CCC(C1C2)c3cc(O)ccc3NC1C(CC(C1COC3=O)[C@]3(CC)O)N2C1=O VUTMVGCVSCMCMQ-QUBRTAAFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553854P | 2011-10-31 | 2011-10-31 | |
| US61/553,854 | 2011-10-31 | ||
| PCT/US2012/062850 WO2013151584A1 (en) | 2011-10-31 | 2012-10-31 | Compound comprising a mao targeting/ seeker moiety for treating human gliomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2887928A1 true CA2887928A1 (en) | 2013-10-10 |
Family
ID=47146760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2887928A Abandoned CA2887928A1 (en) | 2011-10-31 | 2012-10-31 | Compound comprising a mao targeting/seeker moiety for treating human gliomas |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10555936B2 (enExample) |
| EP (2) | EP2804604A1 (enExample) |
| JP (1) | JP6118808B2 (enExample) |
| KR (1) | KR102110794B1 (enExample) |
| CN (1) | CN104136026B (enExample) |
| AU (1) | AU2012376221A1 (enExample) |
| CA (1) | CA2887928A1 (enExample) |
| HK (1) | HK1204547A1 (enExample) |
| WO (1) | WO2013151584A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6118808B2 (ja) | 2011-10-31 | 2017-04-19 | ザ メソジスト ホスピタル リサーチ インスティテュート | ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物 |
| CN104710433B (zh) * | 2014-01-23 | 2016-08-17 | 南京友怡医药科技有限公司 | 苯丁酸氮芥衍生物、制备方法及应用 |
| US10807944B2 (en) * | 2014-04-04 | 2020-10-20 | University Of Florida Research Foundation, Inc. | HDAC inhibitor compounds and methods of treatment |
| US12245355B2 (en) | 2021-02-19 | 2025-03-04 | Mevion Medical Systems, Inc. | Gantry for a particle therapy system |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4913891A (en) * | 1986-04-17 | 1990-04-03 | The United States Of America As Represented By The United States Department Of Energy | Positron emitter labeled enzyme inhibitors |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| JPH09501147A (ja) * | 1993-06-07 | 1997-02-04 | ザ・ウエルカム・ファウンデーション・リミテッド | モノアミンオキシダーゼを使用する免疫反応性試薬 |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5612329A (en) | 1995-06-05 | 1997-03-18 | University Of Maryland At Baltimore | Diaziridinylpolyamine anti-cancer agents |
| WO1998022110A1 (en) * | 1996-11-20 | 1998-05-28 | Virginia Tech Intellectual Properties, Inc. | Prodrugs for the selective inhibition of monoamine oxidase-b |
| KR20010102486A (ko) | 1999-03-03 | 2001-11-15 | 데이비드 엠 모이어 | 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제 |
| US6727361B2 (en) | 2000-11-07 | 2004-04-27 | Symyx Technologies, Inc. | Phosphino substituted pyridine amine ligands |
| US6946479B2 (en) | 2002-11-09 | 2005-09-20 | The Procter & Gamble Company | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones |
| US7943586B2 (en) | 2003-06-09 | 2011-05-17 | The Trustees Of The University Of Pennsylvania | Antineoplastic agents targeted via glut transporters |
| EP1758887A1 (en) * | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
| US7091205B2 (en) | 2004-10-08 | 2006-08-15 | Yu Show Fu | Use of tetramethylpyrazine in the treatment of brain tumor |
| GB0513297D0 (en) | 2005-06-29 | 2005-08-03 | Glaxo Group Ltd | Novel compounds |
| US20070275944A1 (en) | 2006-04-05 | 2007-11-29 | The Board Of Trustees Operating Michigan State University | Antioxidants and methods of their use |
| AR070317A1 (es) * | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
| WO2009111278A2 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| EP2141163A1 (de) * | 2008-07-02 | 2010-01-06 | Bayer Schering Pharma AG | Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| ES2668775T3 (es) * | 2009-06-10 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Compuestos tetracíclicos |
| US8293925B2 (en) * | 2009-09-21 | 2012-10-23 | Chemocentryx, Inc. | Pyrrolidinone carboxamide derivatives |
| JP6118808B2 (ja) | 2011-10-31 | 2017-04-19 | ザ メソジスト ホスピタル リサーチ インスティテュート | ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物 |
-
2012
- 2012-10-31 JP JP2014540047A patent/JP6118808B2/ja not_active Expired - Fee Related
- 2012-10-31 EP EP12783818.3A patent/EP2804604A1/en not_active Withdrawn
- 2012-10-31 EP EP20189611.5A patent/EP3815685A3/en not_active Withdrawn
- 2012-10-31 AU AU2012376221A patent/AU2012376221A1/en not_active Abandoned
- 2012-10-31 KR KR1020147014835A patent/KR102110794B1/ko not_active Expired - Fee Related
- 2012-10-31 CN CN201280064763.1A patent/CN104136026B/zh not_active Expired - Fee Related
- 2012-10-31 CA CA2887928A patent/CA2887928A1/en not_active Abandoned
- 2012-10-31 WO PCT/US2012/062850 patent/WO2013151584A1/en not_active Ceased
- 2012-10-31 HK HK15103179.0A patent/HK1204547A1/xx unknown
-
2014
- 2014-04-30 US US14/266,729 patent/US10555936B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10555936B2 (en) | 2020-02-11 |
| JP2014534227A (ja) | 2014-12-18 |
| KR102110794B1 (ko) | 2020-05-15 |
| US20140323513A1 (en) | 2014-10-30 |
| WO2013151584A1 (en) | 2013-10-10 |
| EP2804604A1 (en) | 2014-11-26 |
| CN104136026A (zh) | 2014-11-05 |
| EP3815685A2 (en) | 2021-05-05 |
| CN104136026B (zh) | 2018-03-02 |
| HK1204547A1 (en) | 2015-11-27 |
| JP6118808B2 (ja) | 2017-04-19 |
| KR20140128943A (ko) | 2014-11-06 |
| AU2012376221A1 (en) | 2014-06-19 |
| EP3815685A3 (en) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8597949B2 (en) | Methods and compositions for modulating RAD51 and homologous recombination | |
| US20120171227A1 (en) | Pro-drug complexes and related methods of use | |
| CN104788523B (zh) | 用于核酸结合物的具有内涵体溶解剂的优化的体内递送系统 | |
| CN113166060A (zh) | 用丙酮酸激酶激活化合物治疗镰状细胞病 | |
| EP2809324A1 (en) | Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer | |
| CN109563088B (zh) | MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途 | |
| US20250249003A1 (en) | Combinations of kras g12d inhibitors with irinotecan and related methods of treatment | |
| CN115433187B (zh) | 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途 | |
| US10555936B2 (en) | Chemotherapeutic compositions and methods for treating human gliomas | |
| US9206193B2 (en) | Substituted norindenoisoquinolines, syntheses thereof, and methods of use | |
| US20140364454A1 (en) | Metal-chelating compounds having at least one polyamino chain | |
| US9566351B2 (en) | Molecular containers and methods of making and using same | |
| US20180360843A1 (en) | Mao inhibitors and their conjugates as therapeutics for the treatment of brain cancer | |
| US10449182B2 (en) | Sorafenib derivatives as p21 inhibitors | |
| HK40041905A (en) | Compound comprising a mao targeting/seeker moiety for treating human gliomas | |
| WO2007067752A2 (en) | Certain compositions and methods of treatment | |
| KR101678865B1 (ko) | 암의 치료에 사용하기 위한 화합물들 | |
| US20130345231A1 (en) | Anticancer therapeutic agents | |
| JP2014534227A5 (enExample) | ||
| AU2018367939B2 (en) | Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity | |
| Zhou | Dendrimer-Based Proteosomal Degradation of Indoleamine 2, 3-Dioxygenase 1 (IDO1) | |
| JP7724030B2 (ja) | 腫瘍の治療における１，４－ジヒドロ－ナフチリジン系誘導体の使用 | |
| US20030153493A1 (en) | Combination cancer therapy | |
| US20050261171A1 (en) | Combination cancer therapy | |
| KR20070108933A (ko) | 알부민 결합성 약물의 안전성 및 효능을 증가시키는 방법및 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20181031 |